Company news

Ocular Therapeutix, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ocular Therapeutix™ to Present Data at the American Academy of Ophthalmology (AAO) 2021 Virtual Annual Meeting

October 27, 2021

Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint

October 21, 2021

Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

October 10, 2021

Ocular Therapeutix™ Announces Appointment of Karen-Leigh Edwards as Senior Vice President of Technical Operations

September 27, 2021

Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors

September 21, 2021

Ocular Therapeutix™ Updates Monthly In-Market Unit Sales of DEXTENZA® Billable Inserts

September 12, 2021

Ocular Therapeutix™ to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 6, 2021

Ocular Therapeutix™ to Present at the H.C. Wainwright Ophthalmology Virtual Conference

August 9, 2021

Ocular Therapeutix™ Reports Second Quarter 2021 Financial Results and Business Update

August 8, 2021

Ocular Therapeutix™ Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases

August 4, 2021

Ocular Therapeutix™ Announces First Patient Dosed in U.S.-based Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet Age-Related Macular Degeneration

July 28, 2021

Ocular Therapeutix™ To Report Second Quarter 2021 Financial Results

July 27, 2021

Ocular Therapeutix™ To Present Clinical Data at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

July 22, 2021

Ocular Therapeutix™ Announces Second Quarter 2021 Preliminary Net Product Revenue of $11.7 Million

July 21, 2021

Ocular Therapeutix™ and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dry Age-Related Macular Degeneration

June 28, 2021

Ocular Therapeutix™ Reports First Quarter 2021 Financial Results and Business Update

May 4, 2021

Ocular Therapeutix™ Fulfills Post-Marketing Approval Requirements for ReSure® Sealant

May 2, 2021

Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

April 28, 2021

Ocular Therapeutix™ To Report First Quarter 2021 Financial Results

April 27, 2021

Ocular Therapeutix™ Reports Fourth Quarter and Year End 2020 Financial Results and Business Update

March 10, 2021

Ocular Therapeutix™ Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

March 3, 2021

Ocular Therapeutix™ Announces First Patient Dosed in Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease

February 28, 2021

Ocular Therapeutix™ To Report Fourth Quarter and Year End 2020 Financial Results

February 24, 2021

Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2021 – Virtual Edition

February 11, 2021

Ocular Therapeutix™ Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients with Primary Open Angle Glaucoma or Ocular Hypertension at the 10th Annual Glaucoma 360 New Horizons Forum

January 19, 2021

Ocular Therapeutix™ Promotes Michael Goldstein, MD, MBA, to President, Ophthalmology and Appoints Rabia Gurses Ozden, MD as Senior Vice President, Clinical Development

January 6, 2021

Ocular TherapeutixTM Announces Exercise of Underwriters’ Option to Purchase Additional Shares

December 27, 2020

Ocular Therapeutix™ Announces Submission to the FDA of a Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

December 21, 2020

Ocular TherapeutixTM Announces Pricing of Public Offering of Common Stock

December 14, 2020

Ocular Therapeutix™ to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

November 22, 2020

Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting

November 10, 2020

Ocular Therapeutix™ Reports Third Quarter 2020 Financial Results and Business Update

November 4, 2020

Ocular Therapeutix Announces Receipt of a Permanent Category I CPT Code from the American Medical Association for the Insertion of Intracanalicular Inserts

November 3, 2020

Ocular Therapeutix™ and AffaMed Therapeutics Announce License Agreement and Collaboration for DEXTENZA® and OTX-TIC in Asia

October 29, 2020

Ocular Therapeutix™ To Report Third Quarter 2020 Financial Results

October 22, 2020

Ocular Therapeutix™ Announces Topline Phase 1 Clinical Trial Results of OTX-CSI

October 7, 2020

Ocular Therapeutix Announces Preliminary Net Product Revenue of $5.8 Million to $5.9 Million for Third Quarter 2020, Representing Greater Than a 250% Increase Over the Previous Quarter

October 6, 2020

Ocular Therapeutix Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

October 5, 2020

Ocular Therapeutix™ Announces First Patients Dosed in Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease

September 28, 2020

Ocular Therapeutix™ Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Post-Surgical Ocular Inflammation and Pain in Children

September 9, 2020

Ocular Therapeutix™ Announces Successful Resolution of FDA Warning Letter Related to ReSure® Sealant

September 7, 2020

Ocular Therapeutix Announces Third Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular Inserts

September 3, 2020

Ocular Therapeutix™ Reports Second Quarter 2020 Financial Results and Business Update

August 6, 2020

Ocular Therapeutix™ To Report Second Quarter 2020 Financial Results

July 30, 2020

Ocular Therapeutix Announces Second Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular Inserts

July 22, 2020

Ocular Therapeutix Presents at the 12th Annual Ophthalmology Innovation Summit (OIS)

July 16, 2020

Ocular Therapeutix Announces Its First Published Physician Fee Schedule for Administration of Intracanalicular Inserts

July 14, 2020

Ocular Therapeutix™ to Present Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

June 14, 2020

Ocular Therapeutix™ to Hold Virtual 2020 Annual Meeting Of Stockholders

June 14, 2020

Ocular Therapeutix™ Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease

May 11, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 14 decks. Every deck is listed under its year.